Brief: Botanix Pharmaceuticals Seeks Trading Halt
25/09/2023 24:11
Sept 25 (Reuters) - Botanix Pharmaceuticals Ltd
BOT.AX :
* SEEKS TRADING HALT PENDING ANNOUNCEMENT ON US FDA
COMMUNICATION
FOR BOTANIX NEW DRUG APPLICATION FOR SOFPIRONIUM BROMIDE GEL
Source text for Eikon: ID:nASX3n0yzj
Further company coverage: BOT.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Botanix Pharmaceuticals
See all newsBrief: Botanix Pharmaceuticals Receives Notice Of Allowance For Additional US Patent Covering Sofdra Drug Substance
Brief: Botanix Pharmaceuticals Appoints Paul Seaback As Chief Operating Officer
Brief: Botanix Pharmaceuticals Reaches Term Sheet Agreement With Second API Supplier
Botanix Pharmaceuticals jumps on supply agreement with PPL Pharma Solutions
Brief: Botanix Pharmaceuticals Posts HY Loss Attributable A$33.2 Million